Ionis Pharmaceuticals（纳斯达克股票代码：IONS）已成功完成其三期临床试验Reveal研究关键队列的患者入组工作，该研究旨在评估药物昂丹司琼（Obudanersen）用于治疗安格曼综合征的疗效。
这项名为Reveal的研究是评估昂丹司琼的关键性试验，其核心队列的入组完成标志着该药物研发进程中的一个重要里程碑。安格曼综合征是一种罕见的神经遗传性疾病，目前治疗选择有限，因此该疗法的进展备受关注。
公司表示，将按计划推进后续的临床试验和数据收集工作，以评估该药物的安全性和有效性。这一进展为潜在的新治疗方案带来了希望，也反映了Ionis在RNA靶向疗法领域的持续探索。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.